Prognostic Impact of the MDM2SNP309 Allele in Leukemia and Lymphoma | Zendy

Sean M. Post | Zendy; Vinod Pant | Zendy; Hussein A. Abbas | Zendy; Alfonso QuintásCardama | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Prognostic Impact of the MDM2SNP309 Allele in Leukemia and Lymphoma

Author(s) -

Sean M. Post,

Vinod Pant,

Hussein A. Abbas,

Alfonso QuintásCardama

Publication year - 2010

Publication title -

oncotarget

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.373

H-Index - 127

ISSN - 1949-2553

DOI - 10.18632/oncotarget.123

Subject(s) - medicine , leukemia , lymphoma , allele , oncology , cancer research , immunology , genetics , biology , gene

A T-to-G germline single nucleotide polymorphism in the promoter region of MDM2 (SNP309) has been reported to markedly accelerate tumor formation in humans suggesting that it may represent a powerful cancer predisposing allele. Since its first description in 2004, a large number of retrospective analyses involving a wide variety of human malignancies have been reported, showing conflicting results regarding the impact of Mdm2SNP309 status on cancer risk and response to cancer therapy. Here, we appraise the available information on the effect of Mdm2SNP309 in lymphoma and leukemia and discuss the factors that likely account for the conflicting results observed in the studies reported to date.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research